Public Voices in Pharmaceutical Deliberations: Negotiating “Clinical Benefit” in the FDA’s Avastin Hearing
- 1 April 2014
- journal article
- Published by Springer Nature in Journal of Medical Humanities
- Vol. 35 (2) , 149-170
Abstract
This article offers a hybrid rhetorical-qualitative discourse analysis of the FDA’s 2011 Avastin Hearing, which considered the revocation of the breast cancer indication for the popular cancer drug Avastin. We explore the multiplicity of stakeholders, the questions that motivated deliberations, and the kinds of evidence presented during the hearing. Pairing our findings with contemporary scholarship in rhetorical stasis theory, Mol’s (2002) construct of multiple ontologies, and Callon, Lascoumes, and Barthe’s (2011) “hybrid forums,” we demonstrate that the FDA’s deliberative procedures elides various sources of evidence and the potential multiplicity of definitions for “clinical benefit.” Our findings suggest that while the FDA invited multiple stakeholders to offer testimony, there are ways that the FDA might have more meaningfully incorporated public voices in the deliberative process. We conclude with suggestions for how a true hybrid forum might be deployed.Keywords
This publication has 24 references indexed in Scilit:
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast CancerJournal of Clinical Oncology, 2011
- Talking Off-Label: The Role ofStasisin Transforming the Discursive Formation of Pain ScienceRhetoric Society Quarterly, 2011
- Avastin's Uncertain Future in Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2011
- Method as Argument: Boundary Work in Evidence‐Based MedicineSocial Epistemology, 2008
- Action Research and Wicked Environmental ProblemsJournal of Business and Technical Communication, 2008
- Accounting for EBM: Notions of evidence in medicineSocial Science & Medicine, 2006
- The problem of evidence-based medicine: directions for social scienceSocial Science & Medicine, 2004
- Two Steps Forward in the Treatment of Colorectal CancerNew England Journal of Medicine, 2004
- Illness, Identity, and Survivorship: Modern and Postmodern Breast Cancer NarrativesIllness, Crisis & Loss, 1998
- The Stases in Scientific and Literary ArgumentWritten Communication, 1988